Efficacy and safety of torasemide in children with heart failure

Archives of Disease in Childhood

Volumn 93, Issue 9, 2008, Pages 768-771

  Senzaki, H ^a   Kamiyama, M ^a   Masutani, S ^a   Ishido, H ^a   Taketazu, M ^a   Kobayashi, T ^a   Katogi, T ^a   Kyo, S ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM; SPIRONOLACTONE; TORASEMIDE; URIC ACID;

ALDOSTERONE BLOOD LEVEL; ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERURICEMIA; HYPOTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SODIUM BLOOD LEVEL; SYMPTOMATOLOGY; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

ALDOSTERONE ANTAGONISTS; CHILD, PRESCHOOL; CHRONIC DISEASE; DIURETICS; FEMALE; HEART FAILURE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 51449106759     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.129239     Document Type: Article

References (19)

1. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38A.
2. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
3. Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
4. Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf 1996;14:104-20.
5. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torasemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57:601-9.
6. Goodfriend TL, Ball DL, Oelkers W, et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998;63:45-50.
7. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991;205:145-50.
8. Fortuno A, Muniz P, Ravassa S, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999;34:138-43.
9. Fortuno A, Muniz P, Zalba G, et al. The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats. Nephrol Dial Transplant 2001;16(Suppl 1):18-21.
10. Yamato M, Sasaki T, Honda K, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003;67:384-90.
11. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111:513-20.
12. Muller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV: efficacy and quality of life. Eur J Heart Fail 2003;5:793-801.
13. Naganuma F, Tsunoda K, Koizumi A, et al. Torasemide improves exercise tolerance and reduces heart rate in daily exercise more than furosemide in patients with chronic congestive heart failure. Jpn J Clin Physiol 2005;35:327-36.
14. Cosin J, Diez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507-13.
15. Cleland JG, Coletta AP, Nikitin NP, et al. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 2006;8:326-9.
16. Connolly D, Rutkowski M, Auslender M, et al. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J Pediatr 2001;138:644-8.
17. Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004;44:2252-3.
18. Pitt B. The role of aldosterone blockade in patients with heart failure. Heart Fail Rev 2005;10:79-83.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.